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a  b  s  t  r  a  c  t
Background:  The  beneﬁcial  effect  of  statins  for cardiovascular  disease  (CVD)  prevention  has  been well
established.  However,  the  effectiveness  among  different  phenotypes  of  dyslipidemia  has  not  been  con-
ﬁrmed.
Objective:  We  evaluated  the  effect  of  pravastatin  on  the  incidence  of CVD  in  relation  to  the  phenotype  of
dyslipidemia.
Methods:  The  MEGA  Study  evaluated  the  effect  of low-dose  pravastatin  on primary  prevention  of  CVD
in 7832  Japanese  patients,  who  were  randomized  to diet  alone  or diet  plus  pravastatin  and  followed  for
more than  5 years.  These  patients  were  classiﬁed  into  phenotype  IIa (n = 5589)  and  IIb  (n = 2041)  based
on  the  electrophoretic  pattern  for  this  post  hoc  analysis.
Results:  In  the  diet  group  there  was  no  signiﬁcant  difference  in  the  incidence  of coronary  heart  disease
(CHD),  stroke,  CVD,  and  total  mortality  between  the  two  phenotypes.  Phenotype  IIb patients,  compared
to phenotype  IIa, had  lower  levels  of high-density  lipoprotein  cholesterol  (HDL-C)  and  a signiﬁcantly
higher  incidence  of  CVD  in  relation  to  a low  HDL-C  level  (<47.5  mg/dL;  p = 0.02).  Furthermore,  pravastatin
decreased  the  relative  risk  for  each  major  endpoint  in  both  type IIa  and  type  IIb dyslipidemia.  Signiﬁcant
risk  reductions  were  observed  for CHD  by 38% (p  =  0.04)  and  CVD  by  31%  (p  =  0.02)  in type  IIa  dyslipidemia
but  not  in phenotype  IIb.
Conclusion:  Pravastatin  therapy  provided  signiﬁcant  risk  reductions  for CHD  and CVD  in  patients  with
ia,  bu
2  Japphenotype  IIa dyslipidem
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Statins have become the most popular cholesterol-lowering
rug in the world. Their protective effect against cardiovascular
isease (CVD) has been proved in a number of large-scale clini-
al studies conducted for both primary and secondary prevention
1–4]. However, atherogenicity and effectiveness of statins among
ifferent phenotypes of dyslipidemia have never been conﬁrmed
n a large-scale trial. Faergeman et al. have shown the association
f increased triglycerides (TG) with risk of recurrence of CVD in
atients treated with simvastatin or atorvastatin using data from
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the incremental decrease in end points through aggressive lipid
lowering (IDEAL) and treating to new targets (TNT) trials and have
suggested there is more risk for CVD in patients with hypercho-
lesterolemia if the TG level is increased [5].  It is considered that
risk remains from atherogenic lipoproteins other than low-density
lipoprotein (LDL) which contribute to CVD in patients treated with
statins.
Plasma cholesterol is carried by lipoproteins such as chylomi-
cron, very-low-density lipoprotein (VLDL), intermediate-density
lipoprotein (IDL), LDL, and high-density lipoprotein (HDL). The
atherogenicity of these lipoproteins differs (considered to be
LDL > IDL > VLDL > chylomicron > HDL) and the response to drugs is
considered to be different. Therefore, knowing which lipoproteins
are increased is important not only to evaluate atherogenicity but
also to select the best drug to treat dyslipidemia. By the patterns
of increased lipoproteins, dyslipidemia has been classiﬁed into six
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henotypes (types I, IIa, IIb, III, IV, and V) [6].  Since LDL is the most
therogenic lipoprotein and the target lipoprotein of statins, the
ost beneﬁcial effect of a statin treatment is expected in patients
ith type II phenotype, deﬁned as dyslipidemia with LDL elevation.
henotype II is further classiﬁed into type IIa and type IIb dyslipid-
mia with VLDL elevation. Even these two phenotypes may  have
ifferent atherogenicity and responses to lipid-lowering drugs. In
ype IIb, small dense LDL is considered to increase with a decrease of
DL, as has been suggested in mixed hyperlipidemia [7].  This indi-
ates the possibility that type IIb has both VLDL and LDL elevation
nd also a qualitative change in LDL into being more atherogenic,
hich could cause statins to be less effective in this phenotype than
n the type IIa phenotype.
In the primary prevention MEGA Study with low-dose
ravastatin in Japanese patients with mild to moderate hyper-
holesterolemia without CVD [8–13], total cholesterol (TC) and
DL-cholesterol (LDL-C) were reduced by 12% and 18%, respec-
ively; HDL-cholesterol (HDL-C) was increased by 5.8%; and,
mportantly, coronary heart disease (CHD) was signiﬁcantly
educed by 33%. In the present post hoc analysis, all the MEGA
tudy patients were classiﬁed according to their dyslipidemia phe-
otype and the incidence of CHD, stroke, CVD, and total mortality,




All 7832 MEGA Study patients were included in the present post
oc analysis. The details of the MEGA Study have been previously
eported [8,9]. Brieﬂy, this prospective randomized, open-label,
linded-endpoint study was conducted between 1994 and 2004
n Japanese men  and postmenopausal women aged 40–70 years
ith a moderate level of hypercholesterolemia (TC concentration:
20–270 mg/dL) without a history of CHD or cerebrovascular dis-
ase. A total of 3966 patients were randomly assigned to the diet
lone group and 3866 patients to the diet plus pravastatin group.
atients in both groups followed the US National Cholesterol Edu-
ation Program (NCEP) step 1 diet [14]. All patients were counseled
y the physician to follow the NCEP step 1 diet for the duration of
he study. Adherence to the diet was evaluated by the physician
ased on patient self-report and recorded in the case report. No
ifference in diet adherence was found between phenotype IIa and
Ib (adherence rate of 0.74 ± 0.17 and 0.71 ± 0.19, respectively). The
ose of pravastatin was 10–20 mg/day, the approved dose range in
apan. Primary endpoints were CHD, deﬁned as a composite of fatal
nd non-fatal myocardial infarction, angina, cardiac sudden death,
nd revascularization procedure. Secondary endpoints were stroke,
HD plus cerebral infarction, all cardiovascular events, and total
ortality. Patients were examined at 1, 3, and 6 months after the
tart of follow-up, and every 6 months thereafter. All subjects pro-
ided written informed consent. This trial was conducted following
he ethical principles of the Declaration of Helsinki and the Japanese
inistry of Health, Labor and Welfare ordinance regarding post-
arket surveillance. The MEGA Study is registered at ClinicalTrials.
ov, number NCT00211705.
lassiﬁcation of the phenotypes of dyslipidemia and other
aboratory measurements
Before patients were randomized to the study, blood sam-
les (plasma) were taken and their phenotype determined. Blood
amples were taken repeatedly over 4 months before the start of
he study and at 1, 3, and 6 months after the start of follow-up and
very 6 months thereafter. TC and TG were measured by enzymaticdiology 61 (2013) 196–200 197
methods and HDL-C was  measured by the precipitation method.
LDL-C was calculated by Friedewald’s formula [15]. All lipid values
and the electrophoretic patterns were measured centrally at the
Special Reference Laboratory (SRL, Hachioji, Tokyo, Japan), which
is certiﬁed for major lipid measurements by the Centers for Disease
Control (Atlanta, GA, USA).
Dyslipidemia phenotypes were determined as follows. Pheno-
type IIa was  determined if the TG level was  <150 mg/dL. If the
TG level was  ≥150 mg/dL, patients were classiﬁed based on the
electrophoretic pattern as run on agarose electrophoresis follow-
ing the method developed by Fredrickson et al. [6].  Phenotype IIb
was determined if the typical pattern of beta and pre-beta bands
(peaks) was  detected. Patients with chylomicron, broad-beta, mid-
band, and a dominant peak of pre-beta band were excluded from
the phenotype IIb group. One member of the steering committee
determined the dyslipidemia phenotype for each patient based on
the electrophoretic pattern provided by the laboratory.
Statistical analyses
The majority of the patients were classiﬁed as type IIa (n = 5589)
or type IIb phenotype (n = 2041); the number of patients with
another phenotype was  small, only 202 in total, and therefore they
were excluded from our analyses. All present analyses to assess the
effect of diet alone and diet plus pravastatin on major endpoints
(CHD, stroke, CVD, and total mortality) by dyslipidemia phenotype
were performed in the type IIa and type IIb phenotypes. Baseline
characteristics were compared between type IIa and type IIb using
the chi-square test for categorical variables or Wilcoxon rank sum
test for continuous variables, and the mean changes in lipid levels
during the follow-up period were compared between the diet alone
group and the diet plus pravastatin group. In the diet alone group,
the incidence of events was  compared between type IIa and type
IIb with and without stratifying type IIb according to mean HDL-C
level (47.5 mg/dL).
The incidence of events was also compared between the diet
alone group and the diet plus pravastatin group by major endpoints
in the type IIa and type IIb phenotypes. Hazard ratios (HRs) and
their 95% conﬁdence intervals (95% CI) were calculated by using the
Cox proportional hazards model adjusted for baseline risk factors,
which were sex, age, hypertension, diabetes, body mass index, and
smoking for major endpoints, plus Lp(a) for stroke.
Results
Patient characteristics
The baseline characteristics of the patients in the type IIa and
type IIb phenotypes are shown in Table 1. Type IIa patients, com-
pared to type IIb, were signiﬁcantly older, included more women
and fewer smokers, and had less hypertension, obesity, and dia-
betes mellitus (p < 0.01). TC levels were similar in both phenotypes.
The LDL-C and the HDL-C levels were signiﬁcantly (p < 0.01) higher
and the ratio of LDL-C/HDL-C was signiﬁcantly (p < 0.01) lower in
type IIa than in type IIb. The TG levels were signiﬁcantly (p < 0.01)
higher in type IIb than in type IIa. The percentage of patients with
metabolic syndrome (MetSyn) was signiﬁcantly higher in type IIb
than in type IIa (64.1% vs 21.2%, p < 0.01).
Changes in plasma lipid levels
Changes in plasma lipid levels are shown in Table 2. In the diet
alone group, TC level was  unchanged. LDL-C was slightly decreased
in type IIa and type IIb by 3.7% and 1.0%, respectively. HDL-C levels
were increased in type IIa and type IIb by 1.8% and 5.6%, respec-
tively. TG levels were unchanged in type IIa and were decreased by
198 M. Nishiwaki et al. / Journal of Cardiology 61 (2013) 196–200
Table  1
Patient characteristics in type IIa and type IIb dyslipidemia phenotypes.
IIa (n = 5589) IIb (n = 2041)
Age (years) 58.6 ± 7.0 57.6 ± 7.6*
≥65 years (%) 23.7 22.0*
Women (%) 73.0 57.9*
Current smoker (%) 12.6 21.2*
Hypertension (%) 39.0 48.7*
Diabetes (%) 20.0 22.8*
Obesity (BMI ≥ 25 kg/m2, %) 27.8 42.9*
BMI  (kg/m2) 23.5 ± 3.1 24.7 ± 3.0*
TC (mg/dL) 242.6 ± 12.0 242.5 ± 12.2
LDL-C (mg/dL) 158.5 ± 16.9 152.3 ± 17.6*
HDL-C (mg/dL) 61.1 ± 14.8 48.8 ± 10.8*
LDL-C/HDL-C 2.8 ± 0.8 3.3 ± 0.9 *
TG (mg/dL) 115.4 ± 44.4 218.5 ± 82.5*
SBP (mmHg) 131.5 ± 17.0 134.1 ± 16.1*
DBP (mmHg) 78.0 ± 10.4 80.1 ± 10.0*
FPG (mg/dL) 107.1 ± 30.2 111.4 ± 33.3*
MetSyn (%) 21.2 64.1*
Data are mean ± SD or percentages.
BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein choles-
terol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; SBP, systolic
blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; MetSyn,



















Fig. 1. Comparison of incidence of events in the type IIa and type IIb dyslipidemia
phenotypes in the diet group. The incidence of events was compared between type
IIa and type IIb (A) and between type IIa and type IIb with above (≥ 47.5 mg/dL) or
below (< 47.5 mg/dL) the mean HDL-C level (B). A Cox proportional hazard model
adjusted for sex, age, hypertension, diabetes, and smoking plus lipoprotein(a) for






* p < 0.01 compared with type IIa phenotype.
.9% in type IIb. The ratio of LDL-C/HDL-C decreased in type IIa and
ype IIb by about 5%. In the diet plus pravastatin group, the decrease
n TC levels was similar in type IIa and type IIb (11.6% vs 11.4%). LDL-
 level was signiﬁcantly decreased in type IIa compared to type IIb
18.6% vs 16.2%, p < 0.01). HDL-C level was increased in type IIa and
ype IIb by 4.5% and 7 .8%, respectively. TG level was unchanged in
ype IIa but decreased in type IIb by 11.8%. The LDL-C/HDL-C ratios
ere similarly decreased by about 20%.
ncidence of major events for type IIa and type IIb dyslipidemia
henotype in the diet group
In the diet group, no signiﬁcant difference was found for the
ncidence of CHD, stroke, CVD, and total mortality between the
ype IIa and type IIb phenotypes (Fig. 1A). Because the HDL-C levels
ere signiﬁcantly lower in the type IIb phenotype than in type IIaTable 1), we further analyzed the incidence of events in the two
henotypes according to below or above the mean HDL-C level
47.5 mg/dL) (Fig. 1B). In patients with above the mean HDL-C, no
ifference was seen between type IIa and type IIb for the incidence
able 2
hanges in plasma lipid levels by treatment (diet alone or diet plus pravastatin) in type II
Diet alone 




TC IIa 2765 237.5 ± 16.6 −2.0% 
IIb 1004 237.3 ± 17.2 −1.9% 0.87 
LDL-C IIa  2765 152.0 ± 18.2 −3.7% 
IIb  985 149.3 ± 19.5 −1.0% <0.01 
HDL-C IIa  2765 61.8 ± 14.4 1.8% 
IIb  1004 50.9 ± 11.1 5.6% <0.01 
TG IIa  2765 119.3 ± 47.5 6.1% 
IIb  1004 194.0 ± 85.5 −9.9% <0.01 
LDL/HDL IIa  2834 2.6 −4.9% 
IIb  1024 3.0 −5.6% 0.10 
ata are mean concentration in mg/dL (percentage change from baseline), unless otherw
C,  total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipo
* IIa vs IIb.of each major event. However, with below the mean HDL-C, the
incidence of events was  generally higher in type IIb patients than
in type IIa patients. Of note, the incidence of CVD was signiﬁcantly
(p = 0.02) higher in type IIb with below the mean HDL-C compared
to type IIa.
a and type IIb phenotypes.
Diet plus pravastatin




IIa 2657 214.2 ± 18.1 −11.6%
IIb 987 215.0 ± 19.2 −11.4% 0.44
IIa 2656 128.7 ± 19.2 −18.6%
IIb 970 126.9 ± 18.9 −16.2% <0.01
IIa 2657 63.2 ± 14.3 4.5%
IIb 987 52.6 ± 11.5 7.8% <0.01
IIa 2657 112.3 ± 43.9 0.8%
IIb 987 188.4 ± 120.4 −11.8% <0.01
IIa 2755 2.1 −22.1%
IIb 1017 2.5 −22.9% 0.07
ise indicated.
protein cholesterol; TG, triglycerides.




































aig. 2. The effects of pravastatin on major endpoints in type IIa and type IIb pheno
5%  CI. CHD, coronary heart disease; CVD, cardiovascular disease; NNT, number nee
he effects of pravastatin on major endpoints in type IIa and IIb
yslipidemia phenotypes
The incidence of each major endpoint and its HR for type IIa and
ype IIb dyslipidemia by treatment group is summarized in Fig. 2.
he number of major endpoints in the diet group was  higher in
ype IIb than type IIa. CHD was 29/1024 (6.3/1000 person-years)
s 49/2834 (3.8/1000 person-years), stroke was 19/1024 (4.1/1000
erson-years) vs 41/2834 (3.2/1000 person-years), and CVD was
2/1024(11.5/1000 person-years) vs 93/2834 (7.3/1000 person-
ears). For each major endpoint, the risk was reduced in both type
Ia and type IIb phenotypes in the diet plus pravastatin group com-
ared to the diet group. Speciﬁcally, CHD was signiﬁcantly reduced
y 38% in type IIa (HR 0.62, 95% CI = 0.40–0.98, p = 0.04) while it
as non-signiﬁcantly reduced by 18% in type IIb (HR 0.82, 95%
I = 0.47–1.42, p = 0.48) with pravastatin. Stroke was reduced by
9% in type IIa (HR 0.71, 95% CI = 0.44–1.15, p = 0.16) and by 46%
n type IIb (HR 0.54, 95% CI = 0.25–1.16, p = 0.11) with pravastatin.
VD was signiﬁcantly reduced by 31% in type IIa (HR 0.69, 95%
I = 0.50–0.95, p = 0.02) whereas it was non-signiﬁcantly reduced
y 31% in type IIb (HR 0.69, 95% CI = 0.45–1.06, p = 0.09). Total mor-
ality was reduced by 21% in type IIa (HR 0.79, 95% CI = 0.50–1.26,
 = 0.32) and by 39% in type IIb (HR 0.61, 95% CI = 0.30–1.25,
 = 0.18). There were no signiﬁcant interactions between groups
nd phenotypes for any endpoints.
afety
There was a similar incidence in type IIa and type IIb phenotypes
or elevations exceeding 100 IU/L for alanine aminotransferase and
spartate aminotransferase. The frequency of abnormal creatine
inase concentrations (≥ 500 IU/L) were the same between type IIa
nd type IIb, and there were no differences between the diet group
nd diet plus pravastatin group. No rhabdomyolysis occurred in any
atients (data not shown).
The incidence of cancer did not differ signiﬁcantly between type
Ia and type IIb phenotypes, nor between the diet group and diet
lus pravastatin group (data not shown).iscussion
Regarding the risks of dyslipidemia, it appears that the risk of
n increased cholesterol level (or TG level) has been evaluated Square size indicates the number of events. Bar represents the relative risk with a
o treat.
focusing on each lipoprotein (LDL and HDL). But dyslipidemia is
a combination of abnormal levels of lipoproteins (probably with
an abnormal qualitative change). Actual patients with dyslipide-
mia  have these combinations, and their risks should be evaluated
in relation to patterns of the combination of dyslipidemia pheno-
types. In terms of hypercholesterolemia (or LDL-C elevation) the
risks should be compared between patients with LDL elevation
alone (type IIa) and those with LDL plus VLDL elevation (type
IIb). This is the ﬁrst study assessing CVD events and the response
to a statin in relation to type IIa and type IIb phenotypes of
dyslipidemia.
In the diet group, although a higher incidence of events was
observed for CHD and CVD in the type IIb phenotype, the differ-
ence was not statistically signiﬁcant (Fig. 1A). We further stratiﬁed
the type IIb phenotype according to mean HDL-C level and analyzed
the incidence of events between the two phenotypes. In patients
with a normal HDL-C level, there was no signiﬁcant difference in
the incidence of major events between type IIa and type IIb. How-
ever, in those with low HDL-C, it was generally higher in type IIb
patients compared to type IIa. Notably, the incidence of CVD was
signiﬁcantly (p = 0.02) higher in type IIb with low HDL-C compared
to type IIa (Fig. 1B). This may  suggest that patients with type IIb
have more potential risk for major events than those with type IIa
if they also have low HDL-C.
The present study also assessed the protective effect of pravas-
tatin on major events in relation to type IIa and type IIb. Pravastatin
was observed to be more beneﬁcial in type IIa than in type IIb, espe-
cially for CHD, which was reduced by a signiﬁcant 38% in type IIa
and by a non-signiﬁcant 18% in the type IIb phenotype (Fig. 2). In
this study, pravastatin reduced LDL-C levels to a greater degree in
type IIa than in type IIb (Table 2), and this might contribute to the
greater protective effect of pravastatin against CHD in type IIa com-
pared to type IIb. Considering that VLDL competes with LDL to bind
LDL receptors, the increased VLDL may  make statins less efﬁcient
in decreasing LDL in type IIb. TG-rich lipoproteins and small dense
LDL are considered to increase with a decrease in HDL in type IIb,
as has been suggested in mixed hyperlipidemia [7].  It is also pos-
sible that pravastatin could not improve the lipoprotein proﬁle in
type IIb as efﬁciently as it did in type IIa in the current study. To
treat type IIb, more aggressive treatment than that for type IIa is
considered to be needed. A higher dose of a statin, switching to a
stronger statin, or the addition of a ﬁbrate or ezetimibe would be
the preferred choice [16,17].
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The difference in the protective effect of a statin between type
Ia and type IIb was particularly recognized in CHD in the present
tudy, whereas for stroke there was no difference in relation to
henotype. Considering that the decreased incidence of CHD is
ttributed to the greater LDL-C reduction in type IIa compared to
ype IIb, it may  be speculated that there is a strong relation between
DL-C level and the incidence of CHD, but not to the incidence
f cerebral infarction. The present study and the subanalysis of
erebral infarction recently reported by Uchiyama et al. [18] may
upport this hypothesis. Pravastatin reduced the incidence of stroke
y 29% in type IIa and by 46% in type IIb. The greater reduction
n the incidence of stroke with pravastatin in type IIb might be
elated to the higher percentage of patients with MetSyn in this
henotype, because it was  observed that stroke was reduced more
n patients with MetSyn than in patients without MetSyn in the diet
lus pravastatin group in a recent post hoc analysis of MetSyn in
he MEGA Study [19].
This study was a post hoc subgroup analysis of the MEGA Study,
n which patients were not classiﬁed by dyslipidemia phenotype
t randomization. The number of patients with phenotype IIb was
ess than half the number with phenotype IIa. This difference was
he result of the narrow range of the TC level (200–270 mg/dL)
equired for study entry. However, there was no difference in
ge, the percentage of women, smoking, hypertension, diabetes,
nd obesity, or the level of TC, LDL-C, HDL-C, LDL-C/HDL-C, TG,
ystolic blood pressure, and fasting plasma glucose, between the
iet alone and the diet plus pravastatin groups for either the
ype IIa or type IIb phenotype (data not shown), enabling us to
ssess the effect of pravastatin on the incidence of events in these
henotypes.
For the comparison between type IIa and type IIb, the statistical
nalyses for the incidence of events were adjusted for baseline
isk factors in the diet alone and diet plus pravastatin groups. No
ifference for the incidence of each event was found by hetero-
eneity testing in either type IIa or type IIb in the diet alone or
iet plus pravastatin groups, which might have been caused by an
nsufﬁcient number of events to detect heterogeneity across the
ategories.
In conclusion, pravastatin therapy provided signiﬁcant risk
eductions for CHD and CVD in patients with type IIa dyslipidemia
ut not in those with type IIb dyslipidemia.
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